In breast cancer, Tranilast modulates the TGF-β signaling pathway by increasing AKT1 phosphorylation and reducing ERK1/2 phosphorylation, causing cell cycle arrest after the G1/S phase. This evidence concerns the gene TGFB1 and breast carcinoma.